p53 constrains progression to anaplastic thyroid carcinoma in a Braf -mutant mouse model of papillary thyroid cancer
Open Access
- 7 April 2014
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 111 (16) , E1600-E1609
Abstract
Significance: We generated a thyroid-specific CreER transgenic mouse and used this strain to model progression of v-raf murine sarcoma viral oncogene homolog B ( BRAF )-mutant papillary thyroid cancer to anaplastic thyroid cancer (ATC). These murine tumors recapitulated the temporal progression and molecular hallmarks of human ATC. We demonstrated that combined mapk/Erk kinase (MEK) and BRAF inhibition resulted in enhanced antitumor activity vs. single-agent BRAF inhibitors in this preclinical model. This model represents a previously lacking mouse model of BRAF -mutant ATC and adds to the experimental armamentarium of a highly lethal disease in need of scientific advances. These data also suggest that potent inhibition of the MAPK pathway may improve outcomes in advanced thyroid cancers.Keywords
This publication has 35 references indexed in Scilit:
- Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid CarcinogenesisMolecular Cancer Research, 2014
- Thyrotropin Signaling Confers More Aggressive Features with Higher Genomic Instability on BRAF V600E -Induced Thyroid Tumors in a Mouse ModelThyroid®, 2014
- Postnatal Expression of BRAFV600E Does Not Induce Thyroid Cancer in Mouse Models of Thyroid Papillary CarcinomaEndocrinology, 2013
- BRAF V600E Inhibition in Anaplastic Thyroid CancerNew England Journal of Medicine, 2013
- mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid CarcinomaThe Journal of Clinical Endocrinology & Metabolism, 2012
- Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid CancerEndocrinology, 2012
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationJournal of Clinical Investigation, 2011
- Targeting the PI3K signaling pathway in cancerCurrent Opinion in Genetics & Development, 2010
- Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid CancerThe Journal of Clinical Endocrinology & Metabolism, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005